New Zealand likes its tech success stories loud: a unicorn valuation, a Nasdaq listing, a founder on a podcast. The more instructive story this week came out of Dunedin. ADInstruments’ technology assisted the research of Karl Deisseroth, a co-winner of the 2026 Nobel Prize in physiology or medicine, the Otago Daily Times reports.
This is a genuine win, and it should be read as one. A firm that has spent decades building specialised equipment for physiology labs now has a direct line to work recognised by the world’s most prestigious science prize. Every lab buyer of instrumentation understands what that signals.
Thirty-five years of doing one thing well
ADInstruments does not make consumer gadgets. In 2025, the company said it had more than 35 years of experience supplying data acquisition hardware and software to thousands of organisations worldwide, used in research and teaching at many of the world’s leading universities.
Its core kit is PowerLab hardware and LabChart software, which record and analyse live physiological signals such as cardiac, respiratory and neural data. The range also covers spirometry devices for respiratory research into asthma, COPD and cystic fibrosis, plus Lt, an online teaching platform that lets students work with real physiological data. Exactly which product Deisseroth’s lab used has not been detailed publicly, and given the range, it is the platform credibility that matters more than the specific box.
The global footprint is not new. Back in 2023, the company ranked 62nd on the TIN200 list of New Zealand’s largest tech exporters, had offices in the USA, UK, China, Australia, India and Brazil, and said Lt was used by 400 universities. It had also acquired Auckland’s Kaha Sciences, which makes implantable wireless devices for recording blood pressure, ECG, EEG and EMG in biomedical research.
The weird stuff pays off
The late Sir Paul Callaghan argued that New Zealand scientists should chase “the weird stuff”, because a small country rarely wins in crowded fields. A Newsroom analysis published in July revisited that idea, noting success tends to come from expertise that looks niche at first and proves unexpectedly useful later.
ADInstruments is the commercial version of that thesis. Physiological data acquisition is not a sector anyone pitches at a dinner party. But it is sticky. Once a university department standardises on a platform for research and teaching, it trains generations of students on it. Those students become principal investigators, and some of them win Nobels.
A thin R&D pipeline behind the headline
The national picture is less flattering. Stats NZ’s latest survey shows business R&D spending of $4.1 billion in 2025, up just 0.4%. R&D as a share of GDP fell from 0.98% to 0.95%, and full-time-equivalent R&D staff dropped 5.1% to 19,000. Manufacturing, where instrument makers sit, contributed 28% of business R&D spend, or about $1.16 billion.
That is happening against a squeeze on margins. Across more than 500,000 businesses, surplus before tax fell 9.4% to $110 billion in the 2025 financial year as expenditure rose faster than income. When profits tighten, long-horizon R&D is often the first line to get trimmed.
The Newsroom piece also warns that government science reforms risk cutting the basic research that feeds future companies, arguing that defunding excellent science to chase commercialisation is “like pulling an apple tree up by the roots to harvest its fruit”. A centre-right government should want commercial returns from public science. The ADInstruments story is a reminder that those returns can take decades to show up, and rarely in the shape officials predict.
Keeping the value at home
There is a second lesson. A University of Auckland analysis of New Zealand’s $133 billion tech sector describes founders building major companies offshore as a “double loss”, missing both the original value and the recycling of talent and capital into the next wave of ventures.
The authors do not argue against going global. They argue the measure that matters is whether firms keep doing R&D here, develop senior technical and management talent locally and feed that back into new companies. A Dunedin headquarters with offices across six other markets is close to the model they describe.
What business should take from it
For founders and investors, the takeaway is that global reach does not require a mass market. It requires being indispensable to a narrow, demanding customer base, and staying there long enough for the credibility to compound. For policymakers, the message is to protect the long, unglamorous pipeline that produces firms like this.
The Nobel will fade from the news within a week. The reference customer will not. Expect ADInstruments’ sales teams to be quoting it in university procurement meetings for years, and expect the next quiet New Zealand export winner to come from somewhere equally obscure, provided the research funding is still there to grow it.
Sources
- Otago Daily Times: ADInstruments’ technology assists Nobel Prize winner’s research (2026-10-12)
- TIN100: TIN member spotlight – ADInstruments (2023-04-19)
- Stats NZ: Research and development survey 2025 (2026-04-23)
- Stats NZ: Annual enterprise survey 2025 financial year (provisional) (2026-06-25)
- Newsroom: Govt science reform uproots the tree it needs to bear fruit (2026-07-31)
- University of Auckland: NZ’s $133 billion tech success – what stays here? (2026-08-18)
Join the discussion
Add useful context, ask a good question, or challenge an idea — keep it specific and respectful.